Angle Share Discussion Threads

[fhmktg] 22/3/2024 07:20

MrK, Bones 698
This looks like a superb area for Portrait+ to check on the influence of this particular drug on the patients disease progress.
Are you going to ask AGL or the Marsden if Parsortix is being used?

[saltraider] 22/3/2024 07:20

@Abbs ... It's OK to adopt a 'TLDR' approach. That's your own business. But I think it's a bit much to ask posters to summarise stuff just so that you can be spoon-fed.

[abbs] 22/3/2024 07:14

Mr K what’s the idiots guide summary please any new news apart for Angle doing another preenestaion?

NHS analysis for 14 day turnaround is certainly great news if it involves Angle.

[mrkeysersoze] 22/3/2024 07:04

For immediate release


22 March 2024



ANGLE plc ("the Company")



PARSORTIX SYSTEM AND ASSAYS BEING SHOWCASED AT A LEADING EUROPEAN BREAST CANCER CONFERENCE



ANGLE presenting two posters highlighting the utility of the Company's new Portrait+ CTC Staining Kit and Portrait HER2 assay





ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce its participation at the 14th European Breast Cancer Conference (EBCC) being held in Milan, Italy on 20 to 22 March 2024.



EBCC is focused on multidisciplinary, high-quality clinical and translational research, with an emphasis on innovation and technology in the management of breast cancer. The conference is attended by researchers, physicians, patient advocates and industry representatives providing sales, partnership and collaboration opportunities.



ANGLE is presenting two posters at the conference:



1. Integrating isolation using label-independent microfluidics and advanced staining for comprehensive Circulating Tumour Cell Analysis



ANGLE's Parsortix® system and Portrait®+ CTC Staining Kit together provide an optimised, efficient, and standardised solution for the harvest and characterisation, via immunofluorescence (IF) staining, of a diverse range of CTC phenotypes. In the presented data, half of the CTC-positive breast cancer patient blood samples contained only mesenchymal CTCs, while half had a combination of both epithelial and mesenchymal CTCs. Patients with purely mesenchymal CTCs would have been missed by epitope-dependent systems. This is important because mesenchymal CTCs or CTCs undergoing epithelial-to-mesenchymal transition are clinically significant, playing a critical role in cancer progression, treatment resistance and metastasis.



CTC clusters harvested by the Parsortix system were observed in 75% of the CTC-positive patients which is crucial given that CTC clusters have been shown to have up to 100 times the increased metastatic potential compared to single CTCs. The Parsortix cassette's unique design is suited to capturing and harvesting clusters which is often difficult with other CTC systems.



The study results highlight the importance of using ANGLE's Parsortix system combined with the Company's Portrait+ CTC Staining Kit, to enable the isolation and analysis of a range of CTC phenotypes and CTC clusters, both of which are important in cancer progression and metastasis.



2. Interrogating HER2 status in Circulating Tumour Cells isolated using the Parsortix® system from Metastatic Breast Cancer patients



The diagnosis and treatment of breast cancer is currently guided by the evaluation of human epidermal growth factor receptor 2 (HER2) status in tissue biopsies. However, a tissue biopsy is invasive, is at a single point in time and, with little opportunity for repeat testing, can become out of date. The longitudinal monitoring of HER2 expression from blood is possible through minimally invasive CTC-based liquid biopsy techniques. ANGLE has developed an IF assay for HER2 protein identification on CTCs isolated and harvested using the Parsortix system from the peripheral blood of metastatic breast cancer (MBC) patients.



Results from an in-house study in 26 patients found that CTCs overexpressing HER2 were present at similar levels in patients that had HER2+ or HER2- tumours by primary tissue biopsy. HER2 status of CTCs was also dynamic, changing over time in 37% of CTC positive donors which is unsurprising given that temporal changes in HER2 tissue status are also well documented in the literature. One third-party study of 575 breast cancer patients similarly found that 38% had changed HER2 status from the original primary tissue biopsy to the metastatic tissue biopsy, at disease recurrence. These initial results using Parsortix-based harvest of CTCs demonstrate how the HER2 status between primary tumours and CTCs can diverge, and that analysis of HER2 expression on CTCs has the potential to help guide clinical decision making in MBC patients, allowing for regular monitoring and tracking of treatment and/or disease progression.



ANGLE Chief Scientific Officer, Karen Miller, commented:

"We are delighted to have had two posters presented at the EBCC conference. The results of these studies further demonstrate the potential utility of ANGLE's sample-to-answer Parsortix system and Portrait imaging assays for reliable and repeatable assessment of biomarkers in a range of solid tumours, including breast. We look forward to discussions with translational researchers and industry representatives at this conference to explore opportunities for sales, collaboration, and partnerships."


Mr K.

[bones699] 21/3/2024 20:04

12p placement on the horizon and that's for the whole company!

[paul planet earth 1] 21/3/2024 13:30

I expect an RNS confirming your brain damage

[havinthelasttoast] 21/3/2024 10:22

Yes rocka. I think so. A placing RNS

[htrocka2] 21/3/2024 10:11

Expect an rns ...before the end of the month.

[havinthelasttoast] 21/3/2024 10:02

Expect a tank very soon. Maybe this afternoon

[bones698] 21/3/2024 09:56

So our trader monkey has turned from buying to shorting this week it seems similar pattern buys and sells on 2 machines. Let's just hope news comes while he's short.

[havinthelasttoast] 21/3/2024 09:04

A good day in the markets this woofer isn’t moving

Placing anyone ?

[5oletrader] 20/3/2024 21:03

What can I say? I like 'pie in the sky.' It helps me understand where the money 'is' + quantify what values are 'possible.'-You stick with 'hot air' and I'll stick with 'pie in the sky.' Job done. Anyway -More EVIDENCE momentum at AGL continues:-HEAD of MOLECULAR SCIENCES:• Reporting to the Senior Director, Head of R&D, the Head of Molecular Sciences is responsible for managing the Molecular Biology groups and activities with the overarching goal of product development.?• The job holder will oversee development of molecular profiling assays and their seamless transition into the ANGLE Clinical Laboratory. This will involve project planning and working across the organisation to deliver projects on time and within budget. The job holder supervises and manages projects that require considerable innovation and agility, and which have a major impact on company performance. The candidate will also act as a company representative in an external-facing capacity, attending conferences, writing papers, giving talks, building relationships and interacting with external KOLs and industry partners. ?• Further, the Head of Molecular Sciences must be able to work across the organisation and, specifically, with other Head of Department, Group Leaders and Directors to ensure success of projects and company goals.-Https://angleplc.peoplehr.net/Pages/JobBoard/Opening.aspx?v=86d34ae4-9112-41bc-acce-396aa55a166c

[havinthelasttoast] 20/3/2024 16:30

Be 10 by start of week.

Something not right here

[adw198] 20/3/2024 16:18

Someone mentioned a Telegram group, anyone have a link? Thanks

[tommo20] 20/3/2024 13:25

5oleTrader, with respect, the potential opportunities that your post refer to are years away. I’m more concerned about the near term and that the company hit their forecast revenue for this year. The figures you are talking about are pie in the sky.

[havinthelasttoast] 20/3/2024 10:45

When this is 8p very soon just think of the toast x

[hoorah henry] 20/3/2024 10:39

What a load of codswallop, you lost out on potential £500k profit you could have banked and now back here with more predictions to suit whatever your agenda is!

[havinthelasttoast] 20/3/2024 10:31

Só a false pump that lasted a few days hehe.

When I buy a share I buy it to hold, the price is nearly 12 again which shows I was spot on to sell. Of course I would love to have been in when the false pump came but there was no substance to it and it fell back quickly. That isn’t investing it’s gambling. I’d rather buy this at 30 or 40p when they actually have a product that people are buying. Not when they are running out of cash and nobody wants the product and they are closing down operations. This company will go bust very soon at this rate. You mugs that are trapped from 70p will never get out and are destined to have a 100 percent loss

[bones698] 20/3/2024 09:25

Lol what am expert

[hoorah henry] 20/3/2024 08:57

HTLT, didn't you buy and sell 2 million shares around the 10 to 12p mark before the rise to 35p?